(688192)"DIZAL PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688192 · · 13 pages · Chinese
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares and Its Persons Acting in Concert Reaching an Integer Multiple of 5% Threshold and Disclosure of Simplified Report on Change in Equity Interests
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of a USD 600 Million Upfront Payment from AstraZeneca for the Global Licensing of ZEGFROVY
- Announcement on Use of Temporarily Idle Self-owned Funds for Entrusted Wealth Management
- Announcement on Shareholding Reduction Plan of Senior Executive
- Announcement on Voluntary Disclosure of Publication of Research Results on Birelentinib for the Treatment of Diffuse Large B-Cell Lymphoma in "Blood Cancer Journal"
Later from Dizal (Jiangsu) Pharmaceutical
All Dizal (Jiangsu) Pharmaceutical news releasesFollow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical